atezolizumab,pembrolizumab
roche,merck
['kcsm,(-skcsm)', 'atezo', 'rcc,(-irccs),(-srcc),(-urcc)']
adjuvant atezolizumab does not improve disease-free survival in patients with rcc #esmo22 #rcc #kcsm #kidneycancer #immunotherapy #oncology
News and views from the world of clinical oncology and hematology